New Jersey is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison of Two Physical Activity Interventions in Individuals With Multiple Sclerosis
NCT02496416
Recruiting
This study will examine the effectiveness of aquatic therapy on a range of MS-related symptoms such as cognition, mood, fatigue and quality of life (QOL).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/01/2022
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)
NCT04663867
Recruiting
The study is designed to evaluate the safety and efficacy of the AngioSafe Peripheral CTO Crossing System.
Gender:
All
Ages:
22 years and above
Trial Updated:
11/22/2022
Locations: American Endovascular & Amputation Prevention, West Orange, New Jersey
Conditions: Peripheral Artery Occlusion, Peripheral Arterial Disease
Register for Updates
Computerized Cognitive Rehabilitation in MS Patients
NCT03729713
Recruiting
This study examines a home-based computerized cognitive rehabilitation intervention in adults with multiple sclerosis compared to placebo (videogame). Patients are assessed through pre-and post neuropsychological testing.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/16/2022
Locations: Robert Wood Johnson Medical School, New Brunswick, New Jersey
Conditions: Multiple Sclerosis, Cognitive Impairment
Register for Updates
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT03428802
Recruiting
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: University Spine Center, Wayne, New Jersey
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
NCT05255107
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Riboflavin 0.23% PESCHKE-L Solution) administered in conjunction with the UV-A li... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: The cornea & Laser Eye Institute-NJ, Teaneck, New Jersey
Conditions: Keratitis, Corneal Ulcer
Register for Updates
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
NCT05255016
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of refractory corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet-A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Peschke Riboflavin 0.25% Transepithelial Solution) administered in conjunction with the UV-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: The cornea & Laser Eye Institute-NJ, Teaneck, New Jersey
Conditions: Keratitis, Corneal Ulcer
Register for Updates
Repetitive Transcranial Magnetic Stimulation to Promote Regeneration in Persons With SCI
NCT05333770
Recruiting
This is a research study to evaluate the safety, efficacy and feasibility of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) in patients with subacute spinal cord injury.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
10/12/2022
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Spinal Cord Injuries
Register for Updates
Reinventing Yourself With Multiple Sclerosis (MS)
NCT05195320
Recruiting
Given the knowledge that detriments in QOL, well-being, and participation are common in MS and attributable in a large part to individual, person-specific factors (e.g., self-efficacy), efforts to develop interventions aimed at addressing these factors is well needed and likely to have a significant impact. The proposed investigation will consist of two phases involving participant recruitment and data collection. Phase 1 will consist of a focus group aimed at identifying the unique needs of ind... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/12/2022
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military
NCT04274543
Recruiting
Knee injuries are common among active-duty military personnel. One of the most common knee injuries is a meniscus tear, which can have several consequences. Immediately, the soldier may be separated from the military for over one year or assigned a permanent activity limiting duty profile. Over time, meniscal tears may also increase the risk of other knee injuries, such as osteoarthritis, which is one of the most common medical reasons for discharge from active duty service. The current standard... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
10/12/2022
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Tibial Meniscus Injuries, Knee Injuries, Knee Injuries and Disorders
Register for Updates
Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury
NCT04136743
Recruiting
Rotator cuff disease (i.e., rotator cuff tendinopathy or tear) is a common cause of shoulder pain in persons with chronic spinal cord injury (SCI). It usually resolves with non-operative treatments such as pharmacological agents and physical therapy; however, when this fails, rotator cuff surgery may be the only option. Corticosteroid injections are another alternative to provide temporary relief, but can over time accelerate degeneration of the tendon and lead to further damage. Autologous adip... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/12/2022
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Spinal Cord Injuries, Tendinopathy, Rotator Cuff Tears, Shoulder Pain
Register for Updates
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
NCT03477604
Recruiting
Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/03/2022
Locations: Deborah Heart and Lung Center, Browns Mills, New Jersey
Conditions: Peripheral Arterial Disease
Register for Updates